Radically different
This drug delivery wearable’s micropump needed an engineered solution for both adhesion and slip. By Philipp Begert, Trelleborg Medical Solutions I want to take you straight to the heart of a project that challenged not only my team’s technical skills, but the fundamentals of medical device engineering. It’s a classic example of requirements in conflict.…
The post Inside the challenging development of a low-friction micropump appeared first on Medical Design and Outsourcing.
NEWS RELEASE: FUCHS Lubricants Co. spotlights NYEMED 7477 high-performance medical grease Engineered for extreme conditions and broad material compatibility FUCHS Lubricants Co., the world’s largest independent lubricant manufacturer, highlights NYEMED 7477, a high-performance, general-purpose grease engineered for medical device environments where durability and patient safety are critical. Designed for applications exposed to thermal stress, mechanical load,…
The post FUCHS highlights NYEMED 7477 grease for medical devices appeared first on Medical Design and Outsourcing.
Cardinal Health reported double-digit growth in pay for its median employee in its latest disclosure of executive compensation. The company also reported lower total compensation for the CEO and two other executives due to a change to the company’s severance plan that boosted the reported value of stock awards the year before the latest disclosure.…
The post Cardinal Health reported a big increase in median worker pay appeared first on Medical Design and Outsourcing.
NEWS RELEASE: WAFIOS Machinery Corporation to host 2nd annual Medical Tech Day showcasing advanced manufacturing solutions for medical components Mokena, IL — WAFIOS Machinery Corporation is proud to announce its 2nd Annual Medical Tech Day, taking place on June 3, 2026, at the company’s Midwest Technical Center in Mokena, Illinois, conveniently located in the greater…
The post WAFIOS hosts 2nd annual Medical Tech Day in Mokena appeared first on Medical Design and Outsourcing.
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
In which RFK Jr. says the “government lies to us” while sitting in front of an HHS seal. Send news tips and podcast recommendations to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.
Last month, a group of 12 Senate Democrats proposed a framework for rebuilding the health care system. The idea was to spur input from others ahead of when Democrats might get a chance to act on those plans.
A single infusion of zorpocabt agene-autoleucel (Zorpo-cel), an autologous CAR T-cell therapy, has led to a rapid and sustained remission in a patient with multiple life-threatening autoimmune disorders, according to a newly reported case published in Med.
Researchers from the University Hospital of Erlangen at Friedrich-Alexander-Universitat Erlangen-Nürnberg in Germany describe how a CD19-targeting CAR T-cell therapy successfully treated a 47-year-old woman suffering from severe autoimmune hemolytic anemia (AIHA), along with immune thrombocytopenia (ITP) and antiphospholipid antibody syndrome (APLAS). All three conditions are driven by malfunctioning B cells that produce harmful autoantibodies attacking the body’s own tissues.
The patient’s condition had proven exceptionally difficult to manage. Over nearly a decade, she had undergone nine different treatment regimens, including steroids, immunosuppressants, and antibody-based therapies, without lasting success. Her AIHA was particularly severe, leaving her dependent on daily blood transfusions and at risk of organ damage due to chronic anemia and iron overload.
With no effective options remaining, the clinicians, under compassionate use, turned to the CAR T-cell therapy developed by Miltenyi Biomedicine. This technique involves collecting a patient’s own T cells, genetically modifying them to target the B cell marker CD19 and reinfusing them to eliminate the dysfunctional immune cells.
The results were striking. Within just seven days of treatment, the patient no longer required blood transfusions. By day 25, her hemoglobin levels had returned to normal, indicating a complete resolution of the hemolytic anemia. Laboratory markers of red blood cell destruction also normalized rapidly.
Equally notable was the therapy’s broader impact. The patient’s elevated antiphospholipid antibodies—responsible for dangerous blood clots in APLAS—fell to normal levels and remained undetectable through 11 months of follow-up. Meanwhile, her platelet counts stabilized, indicating improvement in ITP without the need for additional treatment.
Researchers attribute this success to a “reset” of the patient’s B cell population. Unlike conventional therapies such as rituximab, which partially deplete B cells, CAR T cells appear to achieve deeper and more durable elimination. When B cells eventually returned months later, they were predominantly naïve, suggesting a reprogrammed and healthier immune profile.
Importantly, the treatment was well tolerated. The patient experienced none of the serious side effects commonly associated with CAR T therapy in cancer patients, such as cytokine release syndrome or neurotoxicity. Some mild liver enzyme elevations and blood count abnormalities were observed, likely related to prior treatments and iron overload rather than the therapy itself.
This is the second clinical win for Zorpo-cel in the treatment of autoimmune diseases this year. In January, the Phase I/II basket trial known as the CASTLE trial reported encouraging early results of Zorpo-cel administration in 24 patients with treatment-resistant autoimmune diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM). The therapy showed a favorable safety profile, with no cases of severe cytokine release syndrome or neurotoxicity observed. Efficacy outcomes were strong: 22 of 24 patients met predefined endpoints, including remission in most SLE patients, halted disease progression in all SSc patients, and meaningful clinical responses in the majority of IIM cases.
The case highlights the growing potential of CAR T therapy beyond oncology. Previous studies have shown promising results in systemic autoimmune diseases like lupus, but evidence in hematologic autoimmune disorders such as AIHA has been limited. While the findings are encouraging, researchers caution that this is a single case report. Larger, controlled clinical trials will be necessary to confirm safety, effectiveness, and long-term outcomes across diverse patient populations.
The post CAR T Cells Drive Recovery in Severe Autoimmune Disease Case appeared first on Inside Precision Medicine.
Georg Schett had two things: a young patient deathly ill with lupus, and a couple of mouse studies raising the possibility that special T cells could tame the condition.
The German physician-scientist could produce the cells — chimeric antigen receptors, or CARs — at his institution, which was half the battle. Another hurdle: The patient’s parents. “They were like, ‘Don’t do that. You’re crazy,’” recalled Fabian Müller, Schett’s collaborator at the University of Erlangen-Nuremberg. A widespread fear at the time was that T cells would trigger or worsen autoimmune disease.
The rest of the story is the rare scientific fairy tale: The patient got better. Five years on, she is still in remission, and working in the very clinic where she was treated. Her case upended the world of autoimmune disease, driving a flood of experimentation and investment and offering new hope to millions of patients.